POPULARITY
17 episodes with xbi
8 episodes with xbi
7 episodes with xbi
3 episodes with xbi
9 episodes with xbi
2 episodes with xbi
6 episodes with xbi
2 episodes with xbi
9 episodes with xbi
On this week's episode, Grace Colón, Josh Schimmer, Sam Fazeli, Tess Cameron, Eric Schmidt, and Yaron Werber kick off with a discussion on recent policy moves including the appointment of Vinay Prasad as the director of the FDA's CBER division and nomination of Casey Means for U.S. Surgeon General, noting the impact on the XBI and uncertainty around vaccine gene therapy approvals. The group pondered what kind of regulator Prasad may be, predicting a stricter approach than his predecessor, Peter Marks. The conversation covered the shifting dynamics in vaccine approvals under the new FDA leadership, highlighting that delays like Novavax's flu combo signal heightened scrutiny, with mRNA follow-ons likely to pass under stricter labels, while new vaccines face raised efficacy bars. On the policy front, Trump's proposed “Most Favored Nation” drug pricing strategy raises alarms over a potential trillion-dollar hit to innovation and unintended consequences for U.S. drug prices. The conversation shifts to early data on Genocury's in vivo CAR-T, PTC's mixed Huntington's disease results, and Krystal's gene therapy for neuropathic keratitis. The episode concludes with a roundup of Q1 earnings results. *This episode aired on May 9, 2025.
Biotech indexes are tumbling after one of FDA's last veteran leaders was pushed out by HHS Secretary RFK Jr. and the threat of tariffs weigh on a key biotech index. On the latest BioCentury This Week podcast, BioCentury's editors discuss the factors driving down the XBI, which has now crossed into bear market territory and the latest turmoil at FDA, now that CBER Director Peter Marks has been ousted. Plus, inflammation and immunology companies are finding ways beyond precision medicine to boost responses. BioCentury's editors assess one approach — bispecific antibodies that block two inflammatory pathways instead of one.View full story: https://www.biocentury.com/article/65548800:00 - Introduction00:51 - XBI's Return to the Bear Market11:26 - Marks Ouster & Turmoil at FDA18:07 - Bispecifics for I&ITo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
On this week's episode, hosts Chris Garabedian, Brad Loncar,Sam Fazeli and Yaron Werber cover a busy news week ahead of the J.P. Morgan Healthcare Conference as well as a preview of what to expect next week at the event. Thegroup highlights some of the mega private deals announced, including three that involved the licensing of China assets. The hosts zoom out with a recap of end-of-year reports, the current state of the market and XBI outlook. On the data front, Jasper reports positive Phase 1/2 data for chronic urticaria, Vir shares data for masked T-cell engagers and Stoke moves into Phase 3 with their antisense oligonucleotide for Dravet syndrome. The group also discusses Novo's deal with Valo Health, Galapagos' interesting move with new spin out company, whether we've reached ‘peak obesity' and much more. This episode aired on January 10, 2025.
On this week's episode, Daphne Zohar, Paul Matteis, Brian Skorney, Tim Opler and Abe Ceesay kick off with a more optimistic yet cautious perspective that investor sentiment may be improving. The group notes positive market trends post-JPM with the XBI index rising from 86.5 to around 92 since early January. The discussion also touches on on the re-emergence of wall cross pipes and the impact on generalist investor interest. The hosts discuss the positive M&A outlook for 2025, noting Intra-Cellular's recent acquisition by J&J. Staying on the neuro theme, GH Research announced impressive data from its Phase 2b trial for a short-acting psychedelic drug for treatment-resistant depression. This extended into a discussion on the broader implications of neuropsych drug development, including the need for experienced management and the challenges of patient selection and managing high placebo responses. Other topics discussed include FDA's approval of Axsome's migraine drug, the anti-VEGF therapy competitive dynamics, Trump's tariffs, and more. This episode aired on February 7, 2025.
On this week's episode, hosts Chris Garabedian, Brad Loncar,Sam Fazeli and Yaron Werber cover a busy news week ahead of the J.P. Morgan Healthcare Conference as well as a preview of what to expect next week at the event. Thegroup highlights some of the mega private deals announced, including three that involved the licensing of China assets. The hosts zoom out with a recap of end-of-year reports, the current state of the market and XBI outlook. On the data front, Jasper reports positive Phase 1/2 data for chronic urticaria, Vir shares data for masked T-cell engagers and Stoke moves into Phase 3 with their antisense oligonucleotide for Dravet syndrome. The group also discusses Novo's deal with Valo Health, Galapagos' interesting move with new spin out company, whether we'vereached ‘peak obesity' and much more. This episode aired on January 10, 2025.
During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2024 Q3 Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk's deal team compiles key statistics and trends showcasing the current state of global private and public capital markets, strategic partnerships, and M&A in the biopharma sector. In this episode, Geoff provides valuable insights into our report, focusing on critical areas such as: Biotech capital markets: The XBI rose 7% in Q3, outperforming the S&P 500, driven by strong clinical readouts and strategic deals, with six IPOs showing strong investor demand. Private biotech markets: Venture financing dropped to $3.9B across 41 deals, with average deal size decreasing, while Series A and B deals led the market, showing renewed investor interest in early-stage companies. Strategic transaction activity: Licensing deal value fell by 22%, and M&A shifted to smaller deals focusing on early clinical-stage opportunities, with global deal values remaining down. Market outlook and advice for the months ahead: Locust Walk expects continued momentum in Q4 due to further Fed rate cuts, advises careful cash management, and foresees a stronger recovery by 2025. We invite you to listen to our podcast and read our report and welcome the opportunity to discuss its contents with you. Subscribe or follow Biotalk on Apple Podcasts | Spotify.
How to Trade Stocks and Options Podcast by 10minutestocktrader.com
Welcome to the latest market breakdown on the OVTLYR Trading Room channel! We're diving into some fresh trades and market trends that you won't want to miss. In this video, we're looking at how the OVTLYR system is performing with recent trades. For starters, we've got some solid gains on XBI and XLB calls, which are up by 12.5%, and Walmart, which hit a peak gain of 44%. Walmart alone saw a 43.6% gain before closing, so there's definitely some winning strategy at play here. We'll also touch on the current market signals—SPY is showing bullish vibes, while the staples sector is flipping bearish. It's crucial to adapt your trades based on these shifts, and we'll explain how to adjust your strategy accordingly. One of the highlights is the Golden Ticket Trading Strategy, which is all about turning those small gains into major wins. This strategy, straight from the OVTLYR playbook, is designed to help you find those profitable trades and minimize risks. We'll walk through the decision-making for some of the trades, like the XLF options roll from the 41 to the 42 strike, which turned out pretty well. There's also a quick review of the Halo trade and the final positions on XLB and FI. We'll wrap up with a look at new trade opportunities and how to pick the best stocks. If you're looking to up your trading game, the OVTLYR playbook is available for free at profithackingplaybook.com or in our VIP Investors Toolkit on Discord. It's packed with strategies to help you trade smarter and boost those profits. Don't forget to subscribe to the OVTLYR Trading Room channel to keep up with the latest market analyses and trading tips. Catch you in the next video! Hashtags: #StockMarketAnalysis #TradingStrategies #ProfitHacking #OVTLYR #MarketTrends #TradingSuccess #FinancialFreedom #InvestmentTips #StockTrading
On this week's episode, hosts Josh Schimmer, Sam Fazeli, Brian Skorney, Michal Preminger and Eric Schmidt kick off the show by discussing the recent growth in XBI performance. The group weighs in on IPO dynamics, hypothesizing on the influence of investors and the power of FOMO. They go on to note the success of Viking Therapeutics as they're moving into Phase 3 for their GLP-1 agonist, and what the future may hold for the weight-loss drug market. Shifting gears, the hosts raise concerns on CHMP issuing a negative opinion of Leqembi for Alzheimer's disease, signaling a shift in the relation of CHMP and FDA standards. The group also discusses PBM execs facing heat from the House Oversight Committee as well as recent rare disease news including the FDA's launch of a Rare Disease Innovation Hub. The hosts also highlight the growing success of gene therapy and close the show by discussing one of the top ten rules of engagement for biotech executives. *This episode aired on July 26, 2024.
During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our Q2 2024 Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk's deal team compiles key statistics and trends showcasing the current state of global private and public capital markets, strategic partnerships, and M&A in the biopharma sector. In this episode, Geoff provides valuable insights into our report, focusing on critical areas such as: Biotech capital markets: The XBI remained flat in Q2, diverging from the bullish S&P 500, with fewer IPOs but more capital for later-stage companies. Private biotech markets: Venture financing rebounded with $5.5 billion across 44 deals, though the industry is divided between companies able to raise capital and those struggling. Strategic transaction activity: M&A and licensing deal values stayed consistent with Q1, focusing on Phase 2 companies and notable ex-US acquisitions. Market outlook and advice for the months ahead: Locust Walk expects continued positive momentum, advises careful cash use, notes non-dilutive capital accessibility, and predicts gradual recovery through 2024 with a stronger 2025. We invite you to listen to our podcast and read our report and welcome the opportunity to discuss its contents with you. Subscribe or follow Biotalk on Apple Podcasts | Spotify. Timestamps: 0:39 Deal Context, Quarter Highlights and Key Takeaways, and Future Outlook 8:31 Our Advice for the Current Market Transcription: Welcome to Biotalk. My name is Geoff Meyerson, CEO and Co-founder of Locust Walk, and you are listening to Biotalk, our podcast for biotech deal makers. This episode of Biotalk is focused on Locust Walk's 2024 Second Quarter market conditions Report, in which we apply the latest data to analyze current activities in the biopharma deal landscape. Locust Walk maintains proprietary transaction and finacning databases and each quarter our deal team compiles key statistics and trends showcasing what is happening in the global private and public capital markets and strategic partnering and M&A activity. Deal Context, Quarter Highlights and Key Takeaways, and Future Outlook To provide some structure, I will first cover biotech capital markets, touching on both public and private market performance over the past quarter. I will then transition into strategic transaction activity, covering both M&A and licensing. Please note, the full report published on the Locust Walk website is over 60 slides, so while I will do my best to summarize, as always, I encourage you to check out the full report for additional detail. To download this report, please go to locustwalk.com and go to our “Insights” page. The XBI traded relatively flat across the second quarter, diverging meaningfully from the broader S&P 500, which saw bullish gains. Key drivers of this divergence were the XBI being more impacted by the higher-than-anticipated CPI reading in April relative to the S&P 500 and the record-breaking growth of AI/tech companies. One stunning non-biotech stat to consider: Nvidia alone accounts for more than a third of the S&P 500's gains in 2024. In terms of public fundraising, IPO activity slowed in the second quarter, with only 3 such deals. The weakened macroeconomic outlook and generally poorer performance of first-quarter IPOs reduced market demand for new companies. From my perspective, public biotech markets remain closed to all except a selection of late-stage companies with de-risked approaches, ideally accompanied by insider support and sufficient near-term news flow. Follow-on market activity also cooled from Q1, but interestingly, the average capital raised ($178M) in Q2 is up over 47% relative to the 2023 quarterly average, highlighting the accessibility of large chunks of capital for more de-risked later stage companies with strong data. Venture financing continued its rebound from Q1, with the 44 deals summing to $5.
On this week's Biotech Hangout, hosts Josh Schimmer, Brad Loncar, Tim Opler, Eric Schmidt and Sam Fazeli are joined by special guests Jacob Plieth and Madeleine Armstrong for a deep dive into ASCO 2024, including the highs and lows on the data front. The hosts also discuss the shifting interests from pharma companies as some suggest T-cell engagers may have overtaken ADCs and radios in the oncology space. In non-ASCO news, the group covers NASH data from Lilly and Viking and Structure's data in obesity. The hosts also discuss the latest on BioSecure Act, improving inflation numbers and pickup in the XBI, Moderna's first vaccine approval outside of COVID, and more. This episode aired on June 7, 2024.
On this week's Biotech Hangout, hosts Eric Schmidt, Josh Schimmer, Dawn Bell, Brad Loncar, Tim Opler, Sam Fazeli and Paul Matteis kick off the show by discussing CPI data and how inflation is impacting the $XBI, with analysts hopeful that stability will bring lower interest rates soon. The hosts cover the obesity market, providing updates on new datasets, such as findings from $LLY and $NVO, which indicate promising results in liver fat reduction and potential fibrosis reversal with GLP1+ agents. They also discuss competitive dynamics and investor sentiment of the obesity market and highlight the involvement of various players, including new startups and established pharma companies. In addition, the hosts share updates on Alzheimer's treatments, including takeaways from the EULAR meeting and $LLY's lecanemab panel, alongside the competitive landscape between $LLY, $ESAIY and $BIIB. The hosts also explore the role of patient advocacy within the biotech industry, focusing on $PFE's DMD study and $SRPTA's upcoming PDFUA, the role that patient advocacy groups have on regulatory decisions, and the impact these groups have on influencing industry standards and guidelines. *This episode aired on June 14, 2024.
On this week's Biotech Hangout, hosts Daphne Zohar, Josh Schimmer, Yaron Werber, Luba Greenwood and Dawn Bell start the show with a look at the XBI and M&A activity from the week, including multiple deals topping over $1 billion. The hosts highlight a few of these big transactions, including Biogen acquiring Hi-Bio for $1.15 billion, Merck acquiring Eyebio for $1.3 billion, J&J buying Yellow Jersey for $1.25 billion, and Novartis buying out Mariana for $1 billion, among others. With private acquisitions in the spotlight, the group digs into some of the high caliber private companies emerging in biotech. The group also covers data updates and related stock price reactions from Summit (the company's shares tripled after cancer treatment data), Insmed (shares rocketed following Phase 3 trial results for the company's experimental airway disease drug), Biohaven (its protein-degrader drug falls short of investor expectations), and Roivant's update on FcRn development plans. In a lively discussion, the hosts share varying viewpoints on whether a CEO should respond or comment to criticism on social media, plus they look ahead to ASCO, and more. This episode aired on May 31, 2024.
During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2024 Q1 Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk's deal team compiles key statistics and trends showcasing the current state of global private and public capital markets, strategic partnerships, and M&A in the biopharma sector. In this episode, Geoff provides valuable insights into our report, focusing on critical areas such as: Biotech capital markets: Highlighting XBI's recovery, strong market indicators, and increased PIPE activity since Q2 2023. Private biotech markets: Saw the second-best deal quarter since 2021, yet activity remains flat compared to 2021's robust fundraising Strategic transaction activity: Observing big pharma's large acquisitions, with US M&A lower than Q4 while EU firms showed strong activity. Market outlook and advice for the months ahead. We invite you to listen to our podcast and read our report and welcome the opportunity to discuss its contents with you. Subscribe or follow Biotalk on Apple Podcasts | Spotify. Timestamps: 0:36 Deal Context, Quarter Highlights and Key Takeaways, and Future Outlook 6:23 Our Advice for the Current Market Transcription: Welcome to Biotalk. My name is Geoff Meyerson, CEO and Co-founder of Locust Walk, and you are listening to Biotalk, our podcast for biotech deal makers. This episode of Biotalk is focused on Locust Walk's 2024 First Quarter market conditions Report, in which we apply the latest data to analyze current activities in the biopharma deal landscape. Each quarter, Locust Walk's deal team compiles key statistics and trends showcasing what is happening in the global private and public capital markets and strategic partnering and M&A activity. Deal Context, Quarter Highlights and Key Takeaways, and Future Outlook To provide some structure, I will first cover biotech capital markets, touching on both public and private market performance over the past year. I will then transition into strategic transaction activity, covering both M&A and licensing. Please note, the full report published on the Locust Walk website is over 60 slides, so while I will do my best to summarize, as always, I encourage you to check out the full report for additional detail. To download this report, please go to locustwalk.com and go to our “Insights” page. Q1 of this year continued last quarter's recovery of the XBI and saw a sharp upswing at the end of February on the heels of multiple positive data readouts. The XBI has since normalized but ended Q1 above prior 2023 highs. In support of this positive momentum, we saw several strong indicators of a potential recovery for the public biotech markets. Q1 saw an increase in follow-on offering's volume and deal size (up $8.1B from $3.5B in Q4'23), and a meaningful increase in PIPE volume and size (up $2.6B from $1.7B in Q4'23). We're seeing a trend of increasing PIPE activity that started in Q2 2023, reflecting companies' preference to reduce financing risk by securing capital prior to data announcements, despite the cost of providing less favorable terms. For example, Avidity raised a $400M PIPE, a week before they announced positive data from their Phase 1/2 trial for their lead asset. IPO volume also doubled from Q4, which is positive, although there has been limited activity after the first half of Q1 and the companies going public largely remain limited to later-stage companies. I believe the IPO window is still relatively shut and the public market for early-stage companies will remain challenging, with the two preclinical IPOs, Metagenomi and Fractyl Health, struggling to perform already. To a lesser degree, the private US biotech markets saw some recovery in Q1 with 15 rounds >$100M, the second-best quarter in aggregate deal value since 2021, and nearing the 2023 peak seen in Q3. Overall, activity is still relatively flat when compared to the robust fund...
In this episode, Geoff provides valuable insights into our report, focusing on critical areas such as: Biotech capital markets: XBI performance and IPO volume Private biotech markets: Financing deal value and volume remained flat Strategic transaction activity: Q4 marked a surge in multi-billion-dollar acquisitions Market outlook and advice for the year ahead We invite you to listen to our podcast and download our report for the Insights page and welcome the opportunity to discuss its contents with you. Timestamps: Deal Context: 0:37 Our Advice for the Current Market: 6:11 Transcription: Welcome to Biotalk. My name is Geoff Meyerson, CEO and Co-founder of Locust Walk, and you are listening to Biotalk, our podcast for biotech deal makers. This episode of Biotalk is focused on Locust Walk's 2023 Year-In-Review market conditions Report, in which we apply the latest data to analyze current activities in the biopharma deal landscape. Each quarter, Locust Walk's deal team compiles key statistics and trends showcasing what is happening in the global private and public capital markets and strategic partnering and M&A activity. Deal Context, Quarter Highlights and Key Takeaways, and Future Outlook In the next few minutes, I will provide dealmaking context, highlight events that have had a critical impact on the biotech industry, and provide our outlook for the future along with our advice on how you can survive as a biotech dealmaker. To provide some structure, I will first cover biotech capital markets, touching on both public and private market performance over the past year. I will then transition into strategic transaction activity, covering both M&A and licensing. Please note, the full report published on the Locust Walk website is over 60 slides, so while I will do my best to summarize, as always I encourage you to check out the full report for additional detail. To download this report, please go to locustwalk.com and go to our “Insights” page. As the listener of a biotech podcast, you may well know that this has been a relatively challenging year for the XBI until the middle of the 4th quarter. The index traded below end-of-year 2022 levels for much of the year, but in spite of this, finished up 8% due to a remarkable 4Q rebound. Digging in a little deeper, concurrent with this upswing, Q4 saw a significant uptick in total follow-on offering volume and size (up to $3.5B from $1.4B in Q3), as well as PIPE volume and size (up to $1.7B from $600M). Although IPO volume in the 4th quarter dropped from Q3 levels, annual IPO volume increase 30% from 2022 levels. Performance for IPO, follow-on, and PIPE offerings in Q4 was also generally positive in line with market performance. While all these indicators suggest the beginnings of a gradual thaw for biotech public markets, biotech public investors will be hoping Punxsutawney Phil does not see his shadow come February, heralding another XBI downturn, as was the case in 2023. Unfortunately, winter continued through 2023 for biotech private markets. Overall private financing deal value and volume in 2023 remained relatively flat with the depressed levels observed in 2022. Financing activity continues to be increasingly dominated by clinical stage opportunities, with deal value attributed to these deals increasing from 38% in 2021 to 58% in 2023. Interestingly, the distribution of Series rounds has remained relatively consistent over this period, suggesting that the bar for each financing round stage has risen somewhat uniformly across this period. The general malaise in biotech private financing markets also extended to European and Asian geographies, where 2023 levels remained about on par with 2022, and well below levels observed in the prior bull market cycle. In terms of strategic transaction activity, the string of multi-billion-dollar acquisitions by big pharma in Q4 was the catalyst many of us have been hoping to see for so...
Small caps lagged last year. Is this a buying opportunity? (1:15) - Is 2024 The Year For Small Cap Stocks? (11:30) - Are Biotech Stocks A Good Way To Gain Exposure To Small Caps? (22:15) - How To Find Strong Small Cap Stocks For Your Portfolio? (37:30) - Episode Roundup: IWM, IBB, XBI, BALY, MODG, FNKO, IIPR, DFIN Podcast@Zacks.com
Guest host Nick Shipley, Bio's policy expert joins Daphne Zohar, Brad Loncar, Mike Yee and Yaron Werber on this week's Biotech Hangout. The group discusses policy affecting biotech, including march-in rights, PBMs, IRA and FTC involvement plus bipartisan initiatives like the Orphan Cures Act. They also discuss the state of the XBI and industry sentiment, Bluebird Bio's setbacks following FDA approval and Pfizer's stock after its 2024 forecast revenue. They cover data from Vertex, Icosavax, Arcellx and Legend, plus several ADC deals including Bristol Meyers Squibb, SystImmune, C4 Therapeutics, Merck, Nona Biosciences and Pfizer. Other topics include updates from ASH, the new Amgen CSO plus the group shares their thoughts on what to expect in 2024. *This episode aired on December 15, 2023
On this week's episode of Biotech Hangout, Josh Schimmer, Tim Opler, Chris Garabedian, Dawn Bell and guest host Eric Schmidt, Biotech Analyst, discuss the latest industry news. They cover the JPM year in review, XBI performance, plus Abbvie's acquisition of Cerevel and the implications for Karuna. They also discuss a big GLP-1 deal from Roche and Carmot, the AstraZeneca/ IRA case and EV negative biotechs. They also talk about three big investors days from J&J, Sanofi and Neurocrine Biosciences, plus CVS's update on how they will cover drugs, Eyepoint Pharmaceutical's wet AMD data and much more. *This episode aired on December 8, 2023
Radiopharmaceuticals have experienced a resurgence over the past decade, with a series of approvals, billion-dollar deals and growing sales. On the latest BioCentury This Week podcast, Director of Biopharma Intelligence Karen Tkach Tuzman previews her upcoming analysis of the space, discussing the multidimensional nature of the technology's evolution, and the field's next-wave targets behind PSMA and SSTR2. BioCentury's editors also discuss the legacies of two U.S. lawmakers who won't stand for re-election, Reps. Anna Eshoo (D-Calif.) and Michael Burgess (R-Texas); the latest move by BioNTech to grow its global footprint; and the November rise in the XBI.Music for the 24th Bio€quity Europe promo produced by:Thomas de Paula Eby, Andreas Unge, Epidemic Sound via Getty Images
During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, delves into our 2023 Q3 Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk's deal team compiles key statistics and trends showcasing the current state of global private and public capital markets, strategic partnerships, and M&A in the biopharma sector. In this episode, Geoff provides valuable insights into our report, focusing on critical areas such as: The underwhelming performance of public biotech markets The impact of high-interest rates on biotech companies' capital-raising endeavors The trends of stagnant licensing deals, M&A volume, and deal sizes Advice for the current market and future outlook We invite you to listen to our podcast and download our report for the Insights page and welcome the opportunity to discuss its contents with you. Timestamps: Deal Context: 0:58 Future Outlook: 8:50 Our Best Advice for the Current Market: 11:32 Transcription: Welcome to Biotalk. My name is Geoff Meyerson, CEO and Co-founder of Locust Walk, and you are listening to Biotalk, our podcast for biotech deal makers. This episode of Biotalk is focused on Locust Walk's 2023 Third Quarter market conditions Report, in which we apply the latest data to analyze current activities in the biopharma deal landscape. Each quarter, Locust Walk's deal team compiles key statistics and trends showcasing what is happening in the global private and public capital markets and strategic partnering and M&A activity. Our report covers key takeaways for the sector across US, Europe and Asia geographies for a comprehensive view of biotech dealmaking We invite you to review our report and hope you will find it useful in your business To download this report, please go to locustwalk.com and go to our “Insights” page. As always Locust Walk is happy to speak with you further if you have any questions about our views or if we can be helpful to guide your organization through the current market environment. Deal Context In the next few minutes, I will provide dealmaking context, highlight events that have made a critical impact on the biotech industry, and provide our outlook for the future and our best advice on how you can survive as a biotech deal maker. Jumping right in, public markets has shown poor performance through the third quarter, with the XBI showcasing a decrease in value, down by ~12% since the end of the second quarter This drop brings the XBI back to its position at the end of Q1 2023, with it dropping by 8 percent over the last twelve months, underperforming the S&P which has been up 20 percent over the same period, a staggering 28 percent underperformance. The number of companies trading below cash has increased from June where there was 165 companies, compared to the end of September where there is 196 companies trading below cash. That number is approaching the all time high and is significantly higher than the average of about 25 companies trading below cash, that was seen before the pandemic. The decrease in the XBI is most likely driven by current poor macroeconomic headwinds specifically a high interest rate environment that makes it difficult for biotech companies trading below cash to raise capital Licensing deal flow this quarter was stagnant with the same number of deals as Q2, with average licensing deal value slightly down by 9% from Q2 In contrast to previous quarters, partners are taking a shorter-term view towards licensing deals with a drop in investment in early-stage discovery/pre-clinical assets across modalities and indications, but instead are focusing on assets with Phase 2 data across modalities. However, of the high-profile deals that exceeded $1B in total size, the majority (73%) still involved preclinical/discovery assets and are highly milestone driven; indicating some remaining preference for long-term,
On this week's Biotech Hangout, hosts Brad Loncar, Daphne Zohar, Bruce Booth, Josh Schimmer and Yaron Werber cover the state of the XBI after it hit a 52-week low. They also discuss several deals and financings from the week including Eli Lilly acquiring Point Biopharma ($1.4B) and radiopharma more generally and Sanofi paying Teva to collaborate on inflammatory bowel disease treatment (up to $1.5B). Also Biohaven's offering (~$225M), Amicus Therapeutics' financing with Blackstone ($430M), and Orchard Therapeutics acquired by Kyowa Kirin ($478M). Takeda announces withdrawal of EXKIVITY after its accelerated approval gets pulled, Syndax, ALX Oncology and Roche data and Boehringer Ingelheim launches biosimilar to AbbVie's Humira at an 81% discount. Other topics include Amgen's KRAS inhibitor under FDA review, Exscientia and AI, Ionis Pharmaceuticals' R&D day and Infinity Pharmaceuticals shuts down. *This episode aired on October 6, 2023
On this week's Biotech Hangout, guest Matt Gline, CEO of Roivant, joins hosts Daphne Zohar, Tim Opler, Mike Yee and Yaron Werber to discuss recent Phase 1 data from Immunovant, part of the Roivant family of companies & Igg degraders broadly (BHVN & ARGX). The hosts also cover biotech sentiment, M&A and the state of the XBI. They discuss BridgeBio PIPE funding, Alfasigma acquires Intercept Pharmaceuticals, setbacks for two CD47s (Abbvie and Gilead) and Morphic Therapeutic's controversy. Other topics of discussion include Apellis Favus short report, and Bristol Myers Squibb and AstraZeneca drug pricing negotiations. *This episode aired on September 29, 2023*
Josh Schimmer returns on this week's Biotech Hangout and joins hosts Brad Loncar, Tim Opler, Dawn Bell and Brian Skorney to discuss the industry news of the week. They cover the state of the XBI, IPOs and M&A, plus the ORPHAN Cures Act and low demand for biotech lab space. The hosts also discuss several Phase 3 results from the week (Travere, Iveric, AstraZeneca/ Daiichi Sankyo & Seagen), and partnerships given back to companies (Chiesi gives rights back to Inhibrx & Novartis gives rights back to BeiGene). Other topics include ARS Pharma's CRL from the FDA, Fresh Tracks returning cash to shareholders and AI in biotech. *This episode aired on September 22, 2023
(Airdate 09/08) In this episode I discussed the turbulent history between Africa and France and how the value of Francs is dictated by France regardless of what's going on in the global economy. I also discussed that several former French colonies in Africa still pay a colonial tax. I shared today's crypto & blockchain news including the latest news about XRP Ripple & XBI's adoption announcement.. Please share this week's important shows with Family & Friends. Please visit AheadOfTheCryptoCurve.com
During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2023 Q2 Report: Global Trends in Biopharma Transactions Report. Each quarter, Locust Walk's deal team compiles key statistics and trends showcasing what is happening in the global private and public capital markets, strategic partnering, and M&A. To download this report, please go to locustwalk.com and go to our “Insights” page. We are happy to speak with your team if you have questions about our views or if we can provide any perspective or guidance to your organization. Timestamps: Deal Context: 1:12 Future Outlook: 6:00 Our Best Advice for the Current Market: 7:13 Transcription: Welcome to Biotalk. My name is Geoff Meyerson, CEO and Co-founder of Locust Walk, and you are listening to Biotalk, our podcast for biotech deal makers. This episode of Biotalk is focused on Locust Walk's 2023 Second Quarter market conditions Report, in which we apply the latest data to analyze current activities in the biopharma deal landscape. Each quarter, Locust Walk's deal team compiles key statistics and trends showcasing what is happening in the global private and public capital markets and strategic partnering and M&A activity. Our report covers key takeaways for the sector across US, Europe and Asia geographies for a comprehensive view of biotech deal making. We invite you to review our report and hope you will find it useful in your business. To download this report, please go to locustwalk.com and go to our “Insights” page. As always Locust Walk is happy to speak with you further if you have any questions about our views or if we can be helpful to guide your organization through the current market environment. Deal Context, Quarter Highlights and Key Takeaways, and Future Outlook In the next few minutes, I will provide dealmaking context, highlight events that have made a critical impact on the biotech industry, and provide our outlook for the future and our best advice on how you can survive as a biotech deal maker. To provide deal context (Jumping right in) Jumping right in, public markets have shown some signs of stabilization this quarter, with the XBI exhibiting a slight rebound, up by ~8% since the end of the first quarter Nevertheless, this correction brings the XBI back to its position at the start of 2023, and it remains up only 9 percent over the last twelve months, underperforming the S&P which has been up 16 percent over the same period The number of companies trading below cash has come down from March (212 companies in March, compared to 165 companies in June), but the figure remains significantly elevated and we've largely retraced levels seen at the beginning of the year, which were high relative to historical trends Additionally, the gradual revival of the XBI is driven by a chain of positive licensing deal flow this quarter, with average aggregate licensing deal value up 20% from Q1, to $705M Notably this rise in deal value is accompanied by a 40% decline in deal volume, reflecting the shift towards fewer deals and larger bets In contrast, the venture market which has favored later-stage assets, licensing deals indicate that partners are taking a longer-term view with significant investments in discovery/pre-clinical assets across modalities and indications. This might sound counterintuitive based upon things that we are hearing, but the data doesn't lie and we are still finding early deals being done. M&A dealmaking has been more moderate with an average deal size of $1.5B, which is less than half of the $3.9B in average deal size last from last quarter; keeping the value even this high is largely driven by the Merck / Prometheus deal, and without this deal, quarterly M&A would have fallen in line with the two lowest quarters for deal value in 2022 and average value. Importantly though, 20 deals were completed compared to 13 deals in the first quarter.
If you clean out your closet once in a while, consider doing the same with your investment portfolio. (0:21) Ron Gross and Jason Moser discuss: - Stocks investors should consider trimming like hedges - 2 stocks to throw out altogether - Stocks that spark joy (a la Marie Kondo) - Investments poised for a comeback - Why Visa, Mastercard, and Berkshire-Hathaway are good stocks for a rainy day - Actual cleaning tips! (19:11) Motley Fool senior analyst Bill Mann talks with Howard Marks, co-founder of Oaktree Capital Management, about China's effect on inflation in the U.S. and the winners and losers in a world of higher interest rates. To get your copy of our free report "Top Stocks For Rising Interest Rates" just go to fool.com/interest. Stocks discussed: FIVE, DG, DLTR, OLLI, ZG, UA, COST, CDNS, XBI, PYPL, SQ, BRK, V, MA Host: Chris Hill Guests: Jason Moser, Ron Gross, Bill Mann, Howard Marks Producer: Ricky Mulvey Engineer: Dan Boyd
Is it all bad news in the bear market? Not necessarily. After a tumultuous couple of years, many biotechs are looking for signs of improvement in 2023. After all, the biotech sector felt the market pain acutely, particularly over the last 18 months: 2022 marked the longest period of net negative performance for biotech stocks, with the SPDR S&P Biotech ETF XBI extending net losses over a 70-week period. But things are looking up: the XBI was 7% up in January of this year, and investor sentiment seems to be improving. Biotechs can look forward to some upward momentum if they take the right strategic steps now. In this podcast, Sara Michelmore and Karen Sharma from MacDougall Advisors share what biotechs can do to position themselves for this market swing. See omnystudio.com/listener for privacy information.
Stretávame sa s nimi všade, no ich prítomnosť si takmer neuvedomujeme. Reč je o baktériách, ktoré v sebe skrývajú mnohé neprebádané možnosti. Doposiaľ sú zmapované asi len dve percentá zo všetkých existujúcich baktérií a nájdeme ich aj na miestach, na ktorých by sme ich nečakali. Verejnosť často vníma baktérie negatívne, ako organizmy, ktorými sa môžu ľudia nakaziť a ktoré môžu vyvolať choroby. Pravda je však taká, že život na Zemi existuje predovšetkým vďaka baktériám. V súčasnosti sú baktérie aj kľúčom k liečbe rôznych ochorení. Život baktérií, ich mechanizmus delenia a budovanie odolnosti proti vonkajším vplyvom je fascinujúci a ponúka vede nové možnosti, o ktorých sme sa v podcaste Veda na dosah porozprávali s molekulárnym mikrobiológom doktorom Imrichom Barákom z Ústavu molekulárnej biológie Slovenskej akadémie vied. Dozviete sa o bunkových procesoch, o tom, kde všade sa baktérie nachádzajú, ale aj tom, že väčšina z nich neškodí, práve naopak, pomáha. Baktérie sú dnes dôležitými producentmi rôznych proteínov a látok v biotechnológiách a zároveň sú kľúčové pri výrobe mnohých liekov. RNDr. Imrich Barák, DrSc., je vedúcim Oddelenia mikrobiálnej genetiky Ústavu molekulárnej biológie Slovenskej akadémie vied. Absolvoval viacero stáží na University of Georgia v USA, na University of York a na Oxford University v Spojenom kráľovstve, bol hosťujúcim profesorom na Univerzite v Cagliari v Taliansku a na EPFL vo Švajčiarsku. Dlhodobo sa zapája do európskeho výskumu, kde reprezentuje slovenskú vedu aj ako člen Riadiaceho výboru európskej organizácie Bacell, ktorá spája základný a aplikovaný výskum v Európe v oblasti štúdia a využitia modelového organizmu Bacillus subtilis. Je členom Správnej rady konzorcií SFX a XBI v európskom zariadení XFEL (X-ray Free Electron Laser) v Hamburgu. V roku 2001 mu udelili cenu Vedec roka SR, v roku 2016 sa stal Osobnosťou vedy a techniky v rámci ocenenia Cena za vedu a techniku, v roku 2020 získal Cenu dr. Ludmily Sedlárovej-Rabanovej, v minulom roku bol laureátom ocenenia ESET Science Award v kategórii Výnimočná osobnosť slovenskej vedy a stal sa aj Vedcom roka SR 2020.
Our first Biotalk podcast is focused on Locust Walk's 2022 year-in-review market conditions, which was released the first day of JPMorgan and rapidly accumulated over 500 downloads. Each quarter, Locust Walk's deal team compiles key statistics and trends showcasing what is happening in the global private and public capital markets and strategic partnering and M&A. We wanted to share some insights into the report and discuss key trends, opportunities and predictions for the industry in 2023. To download this report, please go to locustwalk.com and go to our “Insights” page. As always Locust Walk is happy to speak with you further if you have any questions about our views or if we can be helpful to guide your organization through the current market environment. Timestamps: Recap of How We Got Here: 1:03 Key Trends for Biotech Management Teams to Monitor: 4:36 Locust Walk Expectations for 2023 Biotech Market: 6:01 Signals of Market Recovery to Watch For: 9:45 How to be Successful in This Market: 11:19 Transcription: Welcome to Biotalk. My name is Geoff Meyerson, CEO and Co-founder of Locust Walk, and you are listening to Biotalk, our new podcast for biotech deal makers. Our first Biotalk podcast is focused on Locust Walk's 2022 year-in-review market conditions, which was released the first day of JPMorgan and rapidly accumulated over 500 downloads. Each quarter, Locust Walk's deal team compiles key statistics and trends showcasing what is happening in the global private and public capital markets and strategic partnering and M&A activity. We wanted to share some insights into the report and discuss key trends, opportunities and predictions for the industry in 2023. To download this report, please go to locustwalk.com and go to our “Insights” page. As always Locust Walk is happy to speak with you further if you have any questions about our views or if we can be helpful to guide your organization through the current market environment. It's important to review recent history to provide context for the path ahead. The industry became victim of its own success Easy monetary policy with 0% and even negative interest rates in the US and major economies coupled with the success of COVID vaccine development and the intense focus on the biopharma industry to save the world led to a massive wave of biopharma fundraising and industry expansion Starting February 2021, a mere 2 months after the first COVID vaccine approval, the balloon started to deflate with the gradual decline in the XBI and gradual reduction in financings although still occurring at a frenetic pace. In retrospect it is fascinating that the public market was declining yet the volume remaining amazingly high for crossovers, IPOs, and follow-ons. During the 2020 and 2021 boom and from before COVID, way too many companies were created, too much private capital was invested and way too many companies went public leading to an explosion in number of publicly traded biotechs 2022 was a perfect storm of events occurring all at once leading to the first time in memory where macro political and macroeconomics took over control of the industry direction. Over these 12 months the continued aftershocks from COVID and the industry resetting because of too much company supply and too little capital availability created an accelerating negativity to the environment. The Fed hiked rates 4.25% through the course of 2022 in response to the fastest inflation in 40 years, which led to a risk off environment from investors 2022 the XBI fell 25% on the year and 48% since its February 19, 2021 high. IPO issuances stood at only 9 companies compared to 92 in 2021 Companies both public and private have been forced to prioritize their portfolios, focusing on their most advanced viable assets and unfortunately downsize their teams. A consequence of this contraction in pipelines and employment is greater capital efficiency and return on inve...
之前大家在討論Fed升息問題的時候 許多專家鼓勵Fed既然要升息 就學習1980年代的聯準會主席保羅.沃克一次升到底 今天還是請到資深財經專家 慕驊哥 還有股市老司機 私募基金操盤手 陳榮華老師 再來跟大家一同觀察本周的股市 #生活選股達人阿格力 #阮慕驊 #陳榮華 #葡萄王 #華廣 #寶齡富錦 #欣興 #高力 #信驊 #耿鼎 #緯創 #敬鵬 #健鼎 #定穎 #友達 #元大台灣50反1 #聯電 #群創 #臺企銀 #長榮 #新光金 #國泰智能電動車 #長榮航 #中興電 #啟碁 #鴻海 #華通 #寶成 #台新金 #力積電 #中信金 #國泰永續高股息 #中鋼 #兆豐金 #玉山金 #富邦金 #元大台灣50 #元大美債20年 #台泥 #華新 #華航 #京元電子 #台積電 #元太 #中美晶 #頎邦 #華星光 #台半 #廣積 #普誠 #家登 #聯亞 #漢磊 #群聯 #環球晶 #保瑞 #藥華藥 #昇達科 #華新 #永豐金 #仁寶 #英業達 #開發金 #遠東新 #宏碁 #智原 #元大金 #第一金 #大聯大 #標普500 #大陸 #美股 #內資 #IC設計 #蘋果概念股 #光通訊 #金融股 #FED #台股 #股票 #上櫃 #外資 #投信 #自營商 #M1B #M2 #聯準會 #股市 #2年債 #利率 #美債 #升息 #通膨 #鮑爾 #經濟 #生技 #醫療 #高盛 #大型生技製藥類 #XBI #美國製藥 #生命科學 #管理照護 #新能源車 #汽車 #電動車 投資最給力粉絲團：https://reurl.cc/9Xb2zX Podcast 收聽位置：Apple https://reurl.cc/N6Nk5m Spotify https://reurl.cc/LdQ8Y7 Soundon https://reurl.cc/4mbA2Y
Welcome Today's Guest - Crazy Lui Gaming - Co-Host of the XBOX INTERNATIONAL Podcast. XBI is a gaming show that breaks down the biggest news in gaming each week. We talk about every platform even thought our prefer platform may be Xbox. We welcome everyone and encourage healthy and respectful conversations. Twitter: https://twitter.com/CrazyLuiGaming YouTube: https://www.youtube.com/c/CrazyLuiGaming Crazy Lui's Gamer Tag: Crazy Lui #outbreakgamers #xbox #xboxgamepass - Subscribe To Our YouTube Channel - David Anthony's Gamer Tag: WEBDAVE David Anthony is an Xbox Ambassador. Outbreak Gamers website: https://www.outbreakpodcast.com Email us at: outbreakpodcast@gmail.com Order Outbreak Gamers T-shirts & Cool Stuff! https://www.teepublic.com/user/outbreakpodcast Help Support Us By Joining Our Patreon: https://www.patreon.com/outbreakpodcast Filmed On Location at: OUTBREAK STUDIO
Alex Carlson recaps the action in the OTC, NASDAQ, and NYSE. He covers YELL, SIRC, SIGA, GOVX, TOMDF, APDN, XBI, LABU, BCRX, GTHX, OMER, HKD, MEGL, and ILAG. All stocks have been discussed on https://insiderfinancial.com/ To sign up for our FREE alerts and eBook, go to: https://signup.insiderfinancial.com/ To sign up for FREE stocks and trade OTC on WeBull, go to: https://a.webull.com/i/insiderfinancial Disclosure: We have no business relationship with any company whose stock is mentioned in this video. Insider Financial is not an investment advisor; this video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This video is not a solicitation or recommendation to buy, sell, or hold securities. This video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance. For more information, please read our full disclaimer: https://insiderfinancial.com/disclaimer/ yell stock, sirc stock, siga stock, govx stock, tomdf stock, apdn stock, xbi stock, labu stock, bcrx stock, gthx stock, omer stock, hkd stock, megl stock, ilag stock, otc stocks, otc stocks list, penny stocks, penny stocks list, NASDAQ penny stocks, NYSE stocks, NYSE penny stocks #pennystocks #stocks #nasdaq
Stocks rally into Fed – and then blasted higher on a dovish take on Powell. Tech earnings – looking pretty good – well, better than expected. Bond yield tumble, the USD heads lower and asking about the “R” Word. CHECK IT OUT! This episode is sponsored by Masterworks. Sign up today and use the Promo Code TDI Visit http://Masterworks.io Read the Masterworks Disclaimer Looking for style diversification? More information on the TDI Managed Growth Strategy - https://thedisciplinedinvestor.com/blog/tdi-strategy/ eNVESTOLOGY Info - https://envestology.com/ Stocks mentioned in this episode: (BAC), (GS), (MS), (WFC), (TGT), (XBI)
Today we are talking to Yaron Werber. Yaron is Managing Director of Healthcare Biotechnology at Cowen, he has over 20 years of experience as a research analyst and was a founding team member, chief business and financial officer of Ovid Therapeutics. Prior to Ovid Yaron was managing director and head of US healthcare and biotech equity research at Citi.Please note - Between vacation, other work commitments and COVID this conversation was recorded over 2 weeks ago. During that time the tea leave reading of the biotech market has marched forward with people highlighting the double bottom and climb in the XBI. While some have hailed this as the end of the bears and seeing the dust of the raging bulls in the distance I am inclined to ask what hallucinogenic they took the night before. Down rounds and negotiated valuation resets in the private market are starting to become more of a central theme with continued uncertainty about timing to recovery, 2023 is now being discussed. The landslide of public SMID cap companies that need to finance has yet to be realized while the macro economic challenges remain in place with inflation out of control in a backdrop of global destabilization. On the micro side the Seagen life raft is starting to look like a potential mirage with M&A being limited and company consolidation a whisper.In this episode Yaron and I discuss the current market metrics, what companies may want to consider and the challenges to the oft flagged oasis of consolidation, M&A and now the going private plan. We discuss his experience as an operating in a biotech company between his roles in equity research. This experience provides a unique insight into the vagaries of a biotech company and the market.
The penguins are leading the charge - talking us into recession. Markets react and what are you doing? Not looking at your statements? Sticking your head in the sand? So many opportunities - let's find them together. Listener questions and a wake up call. Looking for style diversification? More information on the TDI Managed Growth Strategy - https://thedisciplinedinvestor.com/blog/tdi-strategy/ eNVESTOLOGY Info - https://envestology.com/ Stocks mentioned in this episode: (BAC), (GS), (MS), (WFC), (TGT), (XBI)
Listen in podcast appIn this week's episode of Reformed Millennials, Joel and Cam talk geopolitics and the collapse of Sri Lanka at the hands of Global Elites, the impacts of the USD strength and marketing strategies for successful sporting leagues.PS: The links at the bottom of the newsletter are fantastic this week.It’s a long-term game. Stay the course.Listen on Apple, Spotify, or Google Podcasts.If you aren’t in the Reformed Millennials Facebook Group join us for daily updates, discussions, and deep dives into the investable trends Millennials should be paying attention to.👉 For specific investment questions or advice contact Joel @ Gold Investment Management.📈📊Market Update💵📉Do you see what happens when the US Dollar is falling?Stocks and Crypto go up.This IS the catalyst.Do you want to know what will get stocks and crypto back into bull markets?It's not the fed, it's not the president, it certainly isn't a former president, it isn't a war or any kind of "news" event.It's the US Dollar.The stock market had all the reasons to sell off last week and it didn’t. Many stocks managed to hold and even rally after record and accelerating inflation data. It feels wrong to be bullish while the Fed is still tightening but it is double-wrong not to take long setups when they appear. And we saw some relatively constructive price action towards the end of last week. Some names stood out: SWAV, LNTH, CELH, CCRN, OPCH, LRN, VERU, etc. Keep in mind that none of those has reported earnings yet. One earnings report can end their enthusiasm overnight. This is exactly what happened with the stocks that were showing relative strength during the previous earnings window.Biotech has held the best during the more recent market volatility. XBI tested its 10-day EMA a couple of times and it bounced. The dips are getting bought in the sector. We continue to see constructive price action.The new earnings season has just begun. JP Morgan missed estimates sending most financials to new 52-week lows last Thursday only to see them bouncing strong back the next day. NFLX was last night and TSLA tomorrow alongside a bunch of financials. As always, the reaction to earnings will be a much better signal than actual numbers because it will reveal the current market sentiment. Prices move based on sentiment in a short-term perspective.The Oracle and OXY: "The World Has Changed"Last week, Berkshire Hathaway filed a Form 4 disclosing it purchased another 4.3 million shares of Occidental Petroleum (OXY) for ~$250 million. Berkshire now owns 179.7 million shares of OXY, in addition to the Series A Preferred Stock that it acquired through its 2019 agreement with the company (more on this in a moment). At Friday’s close of ~$59 per share, Berkshire’s stake in the common is now worth ~$10.5 billion (~19% of the company).This story started in May 2019, when Berkshire committed to a $10 billion investment in Occidental preferred stock, contingent upon the completion of its ~$38 billion takeover of Anadarko. (CEO Vicki Hollub in May 2019:)“The Berkshire deal was important to make… the timing was critical… Berkshire could do it in an hour and they could do it on public information… Given the timing that we had, there was no other choice.”)As part of the financing, Berkshire also received warrants; Berkshire has the option to purchase 83.9 million shares at an exercise price of $59.62 per share. (“The preferred stock accrues dividends at 8% per annum and is redeemable at the option of Occidental commencing in 2029 at a redemption price equal to 105% of the liquidation preference plus any accumulated and unpaid dividends, or is mandatorily redeemable under certain specified capital return events. Dividends on the preferred may be paid in cash or, at Occidental’s option, in shares of common stock. The warrants are exercisable in whole or in part until one year after the redemption of the preferred stock.”)When Buffett committed to the $10 billion back in May 2019, here’s what he told CNBC’s Becky Quick about how it came together (by the way, Buffett told Becky in this interview that he was willing to put up $20 billion if needed):“I got a call yesterday evening [on May 5th], which is the first time I’ve talked to Occidental since last Sunday [April 28th]. They told me they were going in this direction, which I like, but I had nothing to do with it. We committed $10 billion, and it had nothing to do with how they framed their offer, how much they offered, or anything else – all they knew was that would be sure that they could get $10 billion from us if they completed the deal with Anadarko.”The ”direction” Buffett referred to was Occidental’s ability to avoid a shareholder vote on its Anadarko bid by raising $10 billion from Berkshire. In (lightly) defending management’s actions, which was loudly questioned by investors like Carl Ichan in his letter to Shareholders here.“I would think if you owned Occidental, you’re bullish on oil over the years – and you’re probably bullish on the Permian Basin because they have such a significant portion of their assets there. So, the idea that they will use less stock and more cash as part of the deal… I would think, net, if I had been an OXY holder at the time, I probably would like that kind of a deal… It’s a bet on oil prices over the long-term more than anything else. It’s also a bet the Permian Basin is what it’s cracked up to be… If oil goes way up, you make a lot of money… You have to have a view on oil over time. Charlie and I have some views on that… We feel good about doing the financing.”(From an Oct 2021 EIA report: “The Permian Basin, which spans western Texas and eastern New Mexico, represents the most prolific hydrocarbon production region in the United States. They accounted for about 30% of U.S. crude oil production and 14% of U.S. natural gas production in 2020.”)After that comment, Becky asked Warren why he didn’t just go ahead and buy all of Anadarko if that’s how he felt; his response was noteworthy:“Well, that might have happened if Anadarko had come to us [directly], but we wouldn’t jump into some other deal that we heard about from somebody coming to us and seeking financing. We hope people come to us on businesses, but I had no idea this transaction was going to happen…”Three years later, in March 2022, it became apparent that Buffett’s interest in OXY went beyond the preferred and the warrants. As discussed in detail at the 2022 Berkshire Hathaway shareholder meeting (held on 05/03/2022) and disclosed in SEC filings, Berkshire started buying OXY common on February 28th, 2022 (it didn’t own a single share before that date). Over a three-week period, Buffett went on a major buying spree: he invested ~$7 billion to buy ~136.4 million shares of OXY (at an average price of ~$51 per share).The initial purchase timing is notable: on February 24th, just a few days before Buffett began buying OXY, Russia invaded Ukraine. Buffett didn’t specifically talk about these geopolitical developments during the shareholder meeting, but he did note that something changed his perception of the bet: “Somebody asked a very good question:"Why weren’t you doing anything on February 20th and why were you doing it, in the case of Occidental, on February 28th? It’s because things developed in a way, and in the case of Occidental specifically, they had an analyst presentation that I read over the weekend… It made nothing but sense, and I decided it would be a good place to put Berkshire’s money… Two weeks later we had 14% of the company… The world changed… We should be very happy that we can produce 11 million barrels a day in the U.S. rather than being able to produce none and having to find those 11 million barrels a day somewhere else in the world to keep the American industrial machine working.”If you're at all interested in why the team and Berkshire are using Oxy as their proxy for energy exposure, i highly recommend listening to the most recent BRK breakdown from colossus podcasts here.💸Reformed Millennials - Post of The Week"Is your business model broken? Are you still making losses after a decade in business? Come talk to the team at TIGER GLOBAL, the leader in bag-holding since 2001!TIGER GLOBAL: We're the greater fool!"From a valuation of $3B to $88M over the past year, after a total of $1.63B in funding. I don’t think there’s been a category with as terrible ROI as food delivery in recent years.Tiger Global is also going from source of envy to ridicule in record time.🐦 Twitter Thread of The Week 🐦Great twitter rant from the ex-ceo of Reddit Yishan.🔮Best Links of The Week🔮Matthew Ball on the Metaverse and Gaming - Tyler Cowan ConversationLifestyles - Morgan HouselRetail Investors Are Buying, Institutions Are Selling - The CompoundChips Act; America, China, and Intel; Micron and TSMC - Ben ThompsonBank of Canada larger-than-expected interest rate hike - CTV News This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.reformedmillennials.com
@AviNMash @AnthonyOhayon and @JoeySolitro are back to discuss Global Unrest, Gamestop, Upstart, and bringing back options trading. 0:00 - Global Unrest 2:00 - Trending Tickers: BTC, $ARKK, $XBI (bio) 6:00 - Upstart $UPST 10:00 Gamestop $GME 12:00 What is the state of Oil | Biden sends to India and China? 16:00 Fed Meeting | State of Economy 21:00 Options Strategies | How to trade in this market. This Episode is brought to you by our Sponsors at StockTwits.com; the thoughts on this podcast are NOT FINANCIAL ADVICE and our own opinions for entertainment purposes only.
Listen in podcast appIn this week's episode of Reformed Millennials, Joel and Cam talk the cultural relevance of TikTok, Canadian fiscal/monetary tightening and the collapse of commodities.- The everything recession- Canadian Housing Crisis Looms large- Who to blame for oil prices?- TikTok is just a platform. But it’s damn good.- Jokic gets 256mm and why pro players need to take to equity instead of sponsorship cashThe links at the bottom of the newsletter are fantastic this week.It’s a long-term game. Stay the course.Listen on Apple, Spotify, or Google Podcasts.If you aren’t in the Reformed Millennials Facebook Group join us for daily updates, discussions, and deep dives into the investable trends Millennials should be paying attention to.👉 For specific investment questions or advice contact Joel @ Gold Investment Management.📈📊Market Update💵📉Hello July.Good riddance to the first half of 2022.It was the worst first half of the year for the S&P since 1970.If we judge by the most constructive charts currently, we can say that the market is pricing a potential recession at some point this year. Look at what is setting up near the 52-week highs list: consumer staples like General Mills (GIS), Dollar General (DG), Post Holdings (POST), Campbel Soup (CPB); auto parts chain Autozone (AZO); online education Stride (LRN); health insurance Humana (HUM); big pharma Merk (MRK) and Eli Lilly (LLY), etc. These are not the type of stocks that lead at the beginning of a sustainable bull run. Biotech is another group showing relative strength over the last few weeks. XBI topped in February of 2021 and it fell 65% in the following 15 months. You have to go all the way to 2000-2002 to see so much destruction in so little time in a sector. The most recent drop overshadows even the Great Recession of 2007-2008. Over the past few weeks, XBI went up above its 20 and 50 dma and successfully bounced off them. It’s a bear market rally but those can be furious.Chinese stocks have been in the doghouse for a long time. The Chinese Tech ETF – KWEB topped in February of 2021 and then it fell 80% in the following 13 months. KWEB seemed to have bottomed in March of 2022 (as of right now) and since then it has made several higher lows, slowly establishing itself above its rising 20 and 50-day moving averages. KWEB is still below its 200-day moving average and the recent push higher can be considered just a bear market rally. And yet, quite a few Chinese ADRs have been acting constructively as of late: breaking out, bouncing off their rising 20-day moving averages.In the meantime, Micron missed earnings and gave a huge cut in guidance bringing down the entire semiconductor index with it. SMH closed at new 52-week lows on Friday – another sign that the market is currently more worried about a recession than inflation and supply chain constraints. The market is not always correct but it’s rarely a good idea to argue with it.MACRO: charts curtesy of all star chartsThe Euro represents almost 60% of the US Dollar Index.So if the Euro is collapsing to new 20-year lows relative to Dollars, that Index is going higher.And this is not a situation where it's just the Euro weakness that's driving things.Both Japanese Yen and British Pounds continue to remain weak.I think it will be very difficult for investors to make money from the long side of stocks or crypto this summer if the US Dollar is breaking out to new highs.A weak Euro breaking down here isn't helping the case for a bottom in stocks.A move lower in Euro would most likely mean a strong leg lower for stocks and crypto.If you're a stock market investor, either in the U.S. or around the world, I think what's happening in the US Dollar needs to be front and center.I say this because during this entire consolidation since 2016, we've seen a very strong negative correlation with stocks.Look at that first Dollar peak in late 2016 - stocks ripped from there. Then look at the next peak in 2020 - stocks ripped from there again.But during this period, when the Dollar wasn't weak, and was strong, like the past year or so, stocks have been under pressure.So I've said it before and I'll say it again. I think we're going to need to see a weak Dollar if we stand to make any sort of real money from the long side this summer.If this is a real breakout in the US Dollar and it's about to make a run towards 120, I don't believe stocks will do well in that environment.Correlations are constantly changing. And this one just might soon. But it hasn't.So we're watching the Dollar here for color on the next direction for stocks.💸Reformed Millennials - Post of The WeekThis article from Untying The Gordian Knot should help those trying to figure out where we are in the economic cycle and when might be a good time to start entering semis.“Dr. Copper has the moniker of the global economy's health as the essential metal used in almost every fixed asset investment (FAI) and manufacturing. It remains vital, although I think Nickel is now equally important in our modern-day lives as it is used in alloying, coatings, and batteries. Iron ore is significant for China's FAI and much more critical than copper in its growth.US Tech sector is 9.3% of the economy and ~ 27-28% of the S&P 500. If one sector is economically essential and broader stock market returns, it is the technology and, more specifically, the Semiconductor sub-sector.Semis has the advantage of having economic data tied to it as well as stocks and indices. What happens in Semis happens in the economy and translates to stock performance almost immediately.”🇨🇦 Important Canadian News From the Week 🇨🇦Canadian HELOC rules set to change.The change will make it so that once the loan's value exceeds 65 per cent of the home, the loan "will operate more like a traditional mortgage where the borrower makes principal and interest payments until the [loan gets back below] 65 per cent," an official told CBC News at a technical briefing.The new rules won't be in force until late 2023, but OSFI says that as things stand now, data from the Bank of Canada suggests there's $200 billion worth of HELOC that is currently outside of that 65 per cent threshold. That's out of $1.8 trillion of total housing debt.🐦 Twitter Thread of The Week 🐦My notes from the thread:Gary Gensler steadfast in opposition to certain policy decisions that Bitcoin enthusiasts have been pushing for. Until the Tether issue is dealt with, Bitcoin exchanges around the world firm up KYC/AML, and the crypto universe submits to regulatory authority, Gensler will never approve a spot Bitcoin ETF🔮Best Links of The Week🔮TikTok is ramping up its ad business, which so far has not been nearly as large as its reach would suggest, but plans to hit $12bn this year. - BloombergWealth vs. Getting Wealthier - by Morgan HouselBill Gurley’s ‘Runnin' Down a Dream’ Presentation - YoutubeIn Defense of Dollar Cost Averaging - Nick MaggiulliRisk Capital and Markets: A Temporary Retreat or Long Term Pull Back? - Musing on Markets (Aswath Damodaran) This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.reformedmillennials.com
Listen in podcast appIn this week's episode of Reformed Millennials, Joel and Cam talk Canadian Politics, the Alberta Budget Surplus and Why Taking Bitcoin as your Salary is a BAD idea.PS: The links at the bottom of the newsletter are fantastic this week.It’s a long-term game. Stay the course.Listen on Apple, Spotify, or Google Podcasts.If you aren’t in the Reformed Millennials Facebook Group join us for daily updates, discussions, and deep dives into the investable trends Millennials should be paying attention to.👉 For specific investment questions or advice contact Joel @ Gold Investment Management.📈📊Market Update💵📉Last week just 2 percent of stocks in the S&P were above 50 day moving average and that generally leads to great forward returns.The market is better at predicting the news than the news is at predicting the market. Financial markets typically look 6-9 months ahead and try to anticipate what could happen. They are currently betting that the Fed’s aggressive tightening policy is going to send the economy into recession and the Fed will have to stop hiking sooner than previously expected. As result inflation expectations are tapering and we saw a major mean reversion last week. The worst-hit groups year-to-date outperformed significantly last week ARKK went up 18%, the cloud ETF – WCLD, went up 15%, biotech XBI went up 14%. In the meantime, the best performing sector year-to-date – oil & gas (XOP), lost 6%, tested its 200-day moving average and it is now down almost 30% from its annual highs.The odds are that this is just another bear market bounce that will eventually be faded again. It is really hard to know how long it can last. The conventional wisdom says that the declining 50 and 200-day moving averages are likely to be major areas of resistance for SPY and QQQ but markets often overshoot. In the meantime, there’s nothing wrong with being nimble and playing the relief rally. If the bounce has legs, we should see more stocks setting up and offering decent risk/reward entry points. As of right now, the number of good long setups is still relatively small.But, the longer term picture continues to be a mess now that all moving averages are pointing down. It will not be medium term easy to get all these averages trending up again. Expect the unexpected.💸Reformed Millennials - Post of The WeekAlberta budget surplus in 20/21 is going be blown out of the water by 21/22.A review should show incredible royalty revenues.The rest of Canada is going to be psyched! More deficits paid for by Alberta!Canadian naturals horizon project is going to pay more than a billion into Alberta’s pockets. (Or Quebecs)GoodLawyer @ Collision:“I truly believe this is going to become Alberta’s decade.”The words spoken by Doug Schweitzer, Alberta’s minister of jobs, economy and innovation, onstage at the Alberta Innovates tech conference Inventures earlier this month.Speaking to a crowd of thousands, Schweitzer added, “You guys are on the map and you’re winning.”Being on the map is a fairly new experience for Alberta’s tech scene. Only in recent years have the maturing tech startups, increased investment capital, and provincial government buy-in led the province to become globally recognized as an emerging tech hub.Alberta tech clearly has some steam. But with the resignation of Premier Jason Kenney, and Minister Schweitzer announcing he does not plan to run for re-election, the future of the province’s tech spending may be up in the air.BetaKit spoke with stakeholders in the sector and gauged their opinion about how the political changes might affect the hard-fought relationship between Alberta tech and the provincial government.“Tenuous to say the least”continued at the link above…🐦 Twitter Thread of The Week 🐦From Michael Shellenberger:🔮Best Links of The Week🔮The Case For EVs - Fred WilsonHas the Consumer Ever Been More Prepared for a Recession? - Ben CarlsonWITH POLITICAL TURNOVER ON THE HORIZON, IS THE PARTY OVER FOR ALBERTA TECH? - BetakitInvisible Asymptotes - Eugene Wei“Proprietary Product Distribution” is Better than Sliced Bread - Tren Griffen This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.reformedmillennials.com
On this week's episode, Agustin shares some preliminary insights from ASCO and dives into both the lack of data from $AFMD and the less than spectacular update from $PDSB. Additionally, yet another biotech company has been acquired and this one is a late stage commercial company! Is there hope for $XBI after all?If you are a fan of this show make sure to like, comment, subscribe and follow me on Twitter @biotech_bros. If you have any questions regarding the product offerings feel free to explore my website biotechbros.com
On this week's episode, Agustin shares his opinion on recent $XBI fluctuations as well as upcoming data readouts from $AFMD. Additionally, he shares his opinion on whether the recently public Amylyx Pharmaceuticals will be successful in obtaining FDA approval for their therapy targeting ALS. Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros
Liz and Jenny take a look at 10 viewers' assumptions and place trades using less capital. Featured symbols include: XBI,MQ, JPM, SOFI, SPY, AMAT, CSCO, SPCE
The world of biotech remains uncertain as the equity markets continue to slide. Despite the sentiment, great buying opportunities remain! On this week's episode, Agustin discuss why purchasing $XBI rarely makes sense in the case of biotech investing and why having a framework can go a long way! Additionally, he discusses some recent updates on high conviction positions and highlights the good news that is coming for $NVAXMake sure to like, comment, subscribe and follow me on Twitter @biotech_bros
欢迎收听雪球和喜马拉雅联合出品的财经有深度，雪球，国内领先的集投资交流交易一体的综合财富管理平台，聪明的投资者都在这里。听众朋友们大家好，我是主播匪石-34，今天分享的内容名字叫现在是买入医药的好时机，来自黄建平。最近一年，美股和港股生物医药指数都跌幅超过50%，股市下跌的原因很难去分析总结，医药行业的基本面并没有变化，大部分是情绪变化，还有部分原因是之前部分公司上涨透支修正后走向另一个极端。这也是正常情况，股市经常走极端，短期最高价和最低价往往是由疯子决定的。拿美股生物医药来说，我们组合中RNAi、细胞治疗、基因编辑、PROTAC等技术平台最近几个月并没有损害价值的基本面变化，但是跌幅也随大势，窃以为，这是难得的加仓机会。前几天我在雪球发帖统计过，美国生科指数XBI每隔几年都会回调30-50%，但仍然屡创新高。强行分析股市下跌并没有意义，只会误导自己和他人，因为人群的情绪无法分析，这也是股市无法预测短期走势的原因。经常情况是，当股价上涨或下跌到一定幅度后，人群就开始自己加戏，越上涨好消息越多，头脑发热买入，越下跌负面情绪越多，纷纷甩卖割肉，再加上杠杆和做空的流行，往往导致巨大的波动。我过去2年很少买港股和A股医药，因为太贵下不了手，这次港股生物医药的巨幅下跌，也是个价格修正的过程，但是下跌过多就是买入机会。为什么我过去认为港股生物医药太贵、而现在可以买了？1、一个公司的内在价值最终由未来现金流的折现决定，医药也不例外，国内metoo扎堆的做法，必然导致大量公司的未来收入不高，甚至难以盈利，一二级市场的狂热产生了泡沫。2、最近一年港股医药平均跌幅已经超过60%，不分彼此的下跌，让一些实力强的公司显现了长期投资价值，窃以为，少数优质公司可以投了。过去2年表现好时，我时常提醒投资者要做好大幅回撤的心理准备，最近应该反过来，不要害怕，生物医药的需求和创新还看不到天花板，生物医药指数还会屡创新高，如果有几年不用的闲钱，现在大概率是长期投资的买入和加仓良机。我从来没有抄底的概念和想法，只能依据确定性和是否便宜来买入，至于是不是底，我不知道，也不相信有人知道。
As 2022 continues, the sentiment within biotech remains poor. The poor performance of large tech companies like $NFLX and $PTON has caused everything to slide. On this week's episode, Agustin discusses what the future may look like within biotech and explains why $XBI continues to slide and why $LPTX is still compelling despite questions around safety.Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros
Despite the excitement behind JP Morgan's annual healthcare conference, $XBI still has taken a nose dive. On this week's episode, Agustin discuss how to find value among the wreckage that $XBI has generated and highlights in particular one company that he believes may get acquired.
Welcome to 2022! On this episode, Agustin discusses the recent pullback from $XBI and what the future may hold for investors in 2022 and what investments might be worthwhile for this year. With JPM around the corner there are multiple opportunities to add. Additionally, he highlights what the new data release from $CRIS might mean for the company going forward. Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros
CRISPR is an exciting space, with a number of companies finally sharing early clinical data in 2021. NTLA benefitted the most from this by doubling in valuation after data release, while the other CRISPR companies continue to trend lower in the XBI bear market. Caribou Biosciences is one of the smaller EV CRISPR companies with their first clinical readout coming up in 2022. In this episode, I go through a short primer on all the CRISPR companies and discuss why I think Caribou will have a great year. 2022 is on track for another exciting year in biotech - despite the early sell off in the XBI. In this episode, I cover the trends to watch including a number of targets in oncology. As well, Curis reported a data update in their two programs: CA-4948 and CI-8993. The stock sold off by 25% but I explain why I plan on continuing to hold the stock. Thank you to InfoPathways for being a sponsor on the show! Check them out for all your biotech IT needs at infopathways.com or call 410-751-9929. Help out the show (or join the discord) by becoming a patron at: https://www.patreon.com/breakingbiotech Follow me on twitter @matthewlepoire Send me an email matthewlepoire@gmail.com www.breakingbiotech.com #breakingbiotech Disclaimer: All opinions expressed by Matt (or his guests) in this podcast are solely his (their) opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt is not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt does not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech
(1:00) - Breaking Down ARK Invest's Performance In 2021 (12:30) - Gaining Exposure To High Flying Tech Stocks (16:00) - Will Inflows Impact How Cathie Woods Will Invest Going Forward? (22:20) - Learning From The Fidelity Magellan Mutual Fund (30:50) - Episode Roundup: ARKK, ARKG, CTRU, QQQ, QQQM, XBI, FMAG Podcast@Zacks.com
This week on the podcast Agustin discusses $XBI and what the future holds for biotech investing in 2022. Additionally, he shares his reactions to recent Lancet publications regarding heterologous vaccine usage and comparing different booster shots. Finally, $NVAX has received its first legitimate regulatory approval from the WHO.Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros
This week on the podcast, Agustin reflects on the biotech sector and the recent price fluctuations in $XBI and highlights while there are several zombie companies that don't have long term potential. Despite these circumstances, $AFMD and $LPTX are exceptions that warrant more capital. Additionally, he reflects on the emergence of a new Covid variant and what that means for manufacturers, investors, and public health officials. Make sure to like, comment, subscribe and follow me on Twitter @biotech_bros
Johnson & Johnson (JNJ), UnitedHealth (UNH), Thermo Fisher Scientific (TMO), Pfizer (PFE), and Abbott (ABT) stocks are among the XLV ETF's top holdings. Cinthia Murphy weighs in on why Pfizer's big news was not all good news for healthcare ETFs. Additionally, she says that all healthcare ETFs combined have $5B year-to-date in inflows. Top healthcare ETF flows include XLV, XBI, and VHT.
The U.S. GDP reading tells us the economy might be slowing down. Is that bad for SPY? TSLA is the biggest global automaker by a mile. Jermal addresses these timely topics, and looks at option flow in TSLA, XBI, LCID and FSR.
The U.S. GDP reading tells us the economy might be slowing down. Is that bad for SPY? TSLA is the biggest global automaker by a mile. Jermal addresses these timely topics, and looks at option flow in TSLA, XBI, LCID and FSR.
The gals talk about how volatility affects the pricing of butterflies, look for a bullish trade in corn, and debate hitting that close all button.Featured Symbols: MRK, TLT, RIO, XBI, AMD, ATVI, PDD, LVS, and ARKK
The gals talk about how volatility affects the pricing of butterflies, look for a bullish trade in corn, and debate hitting that close all button.Featured Symbols: MRK, TLT, RIO, XBI, AMD, ATVI, PDD, LVS, and ARKK
It's "What's Your Assumption" Wednesday! Liz and Jenny come up with trades based on viewers' directional bias and account size.Featured Symbols: COG, T, CMCSA, DOCU, MRK, AMGN, CCJ, NKE, CLF, WYNN, COF, and XBI
It's "What's Your Assumption" Wednesday! Liz and Jenny come up with trades based on viewers' directional bias and account size.Featured Symbols: COG, T, CMCSA, DOCU, MRK, AMGN, CCJ, NKE, CLF, WYNN, COF, and XBI
What's going on with inflation and economic growth? No one knows really. July CPI inflation data points to a slight moderation in YoY growth. Consumer sentiment is waning in the face of the delta variant. Melting together with a successful bond auction this week, the 10 year treasury yield bounced before returning to 1.29%. And so we observe lower highs on the way down within a predictable range.A guy from the Macro Voices podcast from the Economic Cycle Research Institute echoes Raoul Pal, predicting slower than expected growth based on industrial data. Which could set the stage for a correction (~10% drawdown) later on. Maybe.But forget that for a second. Greg plagiarizes Carter Worth, who eyes a Fibonacci retracement in XBI (Biotech) as a buying opportunity. To quote the venerable Carter, it's gotten so bad it's good. But just to make it interesting, Greg buys LABU again (triple leveraged bull XBI).Finally we return to Ethereum, where upward price action has defied gravity. RSI suggests we are still overbought. And if recent history is any indication, we might be on the doorstep of a pullback. But where is support now? Our guess...somewhere around ~2,600.And just for fun, Bitcoin!
David Faber, Leslie Picker and Mike Santoli kicked off the show with look at the markets as the Dow aims to post a fourth straight weekly gain. They focused on what you should make of the "stealth correction", featuring some of the areas in the underlying market that have experienced "pain" this week, reflected in groups such as oil services (OIH) and biotech (XBI) as well as the Russell 2000. Banks and yields also in focus with earnings and Fed news dominating the week. The anchors reacted to what Treasury Secretary Janet Yellen told CNBC about expecting "several more months of rapid inflation" before it declines "back toward normal levels" -- plus "Bond King" Jeffrey Gundlach saying stocks still remain cheap compared to bonds. On the M&A front, the anchors discussed that Intel is reportedly in talks to acquire chipmaker GlobalFoundries for about $30-billion, which would be Intel's largest acquisition ever. Cruise ships also in the spotlight: Canada announcing it will allow cruises to resume in November if certain health guidelines are met. The anchors engaged in a roundtable discussion with analysts who cover the cruise lines, whose shares are among the worst performers on the S&P 500 this month. Also in focus: Los Angeles County to resume indoor mask mandates as the COVID-19 Delta Variant continues to spread, Moderna shares surging on news it will be added to the S&P 500, Didi slumps again on new developments surrounding a Chinese cybersecurity probe, June retail sales come in better than expected, investors flocking toward big tech, and Apple employees reportedly saying the company is cracking down on remote work.
Welcome all once again. The stock market pushes up late last week. IWM hit the top of the channel and remain there for a possible breakout. EWZ in pull-back mode. Formed a short-term double top. The energy sector pushing up slowly. Oil is holding its strength. RSX and INDA in consolidation mode. EEM, FXI and XBI are looking bullish. Look out for a new podcast. Crypto Weekend with Trade Doc debuting next Saturday. View this episode's video on my Youtube channel below. https://www.youtube.com/channel/UCNI13o7mV_LzcjFAXUgC9Iw https://www.theta.tv/tradedoc --- Send in a voice message: https://anchor.fm/tradedoc/message Support this podcast: https://anchor.fm/tradedoc/support
Liz and James place the trades generated by Alpha Boost. Features symbols include: EWZ, GPS, RKT, IWM, XBI, and NUE.
Liz and James place the trades generated by Alpha Boost. Features symbols include: EWZ, GPS, RKT, IWM, XBI, and NUE.
When calculating our covered call writing returns, there are 2 sets of computations that shouldn't be confused. One is the calculations we use to make the best trading decisions at any given point in time. The other relates to analyzing the overall success of our trading. A real-life example with XBI is analyzed with the assistance of the ellman Calculator. BECOME A BCI MEMBER TODAY: https://www.thebluecollarinvestor.com/membership/ SEE BCI COURSE & PRODUCTS : https://thebluecollarinvestor.com/store/ STOCKS,TRADING,STOCK MARKET,COVERED CALLS,covered call writing,Axsome,Therapeutics,Ellman Calculator,gap-up,cost-to-close,implied volatility,Alpha,Beta,seeking,alpha,cost-basis,time-value,intrinsic- value,put-selling,collar calculator,put calculator,stock option,facebook stock,amazon stock,investing,options,Option,option buyer,strike price,in the money,in the money coverd call,out of the money covered call,covered call writing exit strategies
Liz and Jenny spin the wheel and place a high probability trade in XBI. Liz then addresses what she looks for each Friday morning in her account.
Liz and Jenny spin the wheel and place a high probability trade in XBI. Liz then addresses what she looks for each Friday morning in her account.
Find out why the research team is selling undefined risk in XBI, TWTR, INTC, EEM, and SNAP.
Find out why the research team is selling undefined risk in XBI, TWTR, INTC, EEM, and SNAP.
Tony has 2 trade ideas for this 4/20! A Broken Wing Butterfly in the ETF, XBI & a $20 wide Iron Condor in QQQ. Tune in for the setups and why he likes these trades. The QQQ trade was based on the Market Measure study on tastytrade.com
As out-of-the-money premium sellers, we frequently put ourselves in a position to benefit from not only directional moves in our favor, but also from the simple passage of time. Most of our strategies are inherently structured in this way. And with our Ratio Spread in XBI and our Diagonal Spread in USO, we see two real-time examples of how these metrics can work together to create profitable trades.
As out-of-the-money premium sellers, we frequently put ourselves in a position to benefit from not only directional moves in our favor, but also from the simple passage of time. Most of our strategies are inherently structured in this way. And with our Ratio Spread in XBI and our Diagonal Spread in USO, we see two real-time examples of how these metrics can work together to create profitable trades.
Ratio Spreads are great strategies that offer versatility and flexibility that is difficult to find anywhere else. With the potential to profit from a directional move in either direction, they can be used with either a bullish or bearish bias in the market. When executing a Ratio Spread, however, one of the choices that has to be made is to use a wide spread or a narrow spread. Not surprisingly, there are pros and cons to both choices, so today we take a look at what these pros and cons are with our potential Ratio Spread in XBI.
Ratio Spreads are great strategies that offer versatility and flexibility that is difficult to find anywhere else. With the potential to profit from a directional move in either direction, they can be used with either a bullish or bearish bias in the market. When executing a Ratio Spread, however, one of the choices that has to be made is to use a wide spread or a narrow spread. Not surprisingly, there are pros and cons to both choices, so today we take a look at what these pros and cons are with our potential Ratio Spread in XBI.
Brad Loncar weighs in on JNJ, MRNA, PFE, VRTX, IBB, XBI, SRNE, and VIR. He says that investors should be skeptical of biotech companies that suddenly announce clinical trial news as these stocks will eventually be valued on the fundamentals.
References Greg coined the term "swiss army knife for your money" - CashApp Boosts, Bitcoin, Fractional Shares Greg discuses some macro trends impacting our lives, and how to futureproof your accounts. Check out EEM, IBB, XBI, UUP, /SFX, ALB, LIT Other Places to Find Us twitter Facebook Instagram YouTube pinterest MoneyVikings.com --- Support this podcast: https://anchor.fm/moneyvikings/support
(0:30) - 2020 ETFs To Keep On Your Radar What ETFs did everyone dive into as the coronavirus pandemic hit? The list may surprise you. (2:40) - Where Are Investors Pouring There Money Into: ETF Trends (8:15) - Breaking Down The Cannabis ETFs (11:00) - Newly Launched ETFs (14:50) - Funds That Will Benefit From Coronavirus Vaccines and Treatments (21:15) - Is It A Good Time To Invest In The Housing Industry (25:00) - Gold And Silver ETFs Trending With Investors (33:50) - Episode Roundup: Podcast @Zacks.com GLD, QQQ, USO, XLK, JETS, MJ, BETZ, NERD, GUSH, GERM, XBI, IBB, WFH, XHB, ITB, SLV, SIVR, GLDM, GLX, GDXI
Welcome all again. This week was volatile with no opening of positions in options. Oil market and XBI and XLV are looking good with XLU and IYR testing highs. May be time to short the bonds. Keep cash on the side and execute when things are looking good. --- Send in a voice message: https://anchor.fm/tradedoc/message
Thoughts and Trading with Trade Doc. Looking for buying opportunities in XBI, GDX, and MJ sector. IWM and small caps holding their own. Energy sector XLE looking to stabilize. Why go long EWZ, EWW, EEM and INDA. Shorting futures in /CL and /NQ --- Send in a voice message: https://anchor.fm/tradedoc/message
Thank you all for Joining me Spoke about the positions built on MJ ETF. Oil drops but XOP looks like it could bounce. GLD and GDX on the watch. HOt ETFs: EEM, EWW, FXI, XBI, XLV, INDA, MJ --- Send in a voice message: https://anchor.fm/tradedoc/message
Thank you all for joining me and Happy Easter. Check out the strength in FXI, INDA, and RSX. EEM, EWZ and EWW keeping positive delta. XLB and XLI my be topping out. Looking to buy the dip in XLV, XBI, MJ, and PPH The rest of the markets looks like they will consolidate withing the 2 week ranges. Volatility should come up to make a traders market for the week. --- Send in a voice message: https://anchor.fm/tradedoc/message
Now Summer is around the corner. Traders have done well doing nothing but buying since the beginning of the year. Discussed recent price action of broad markets. A little on options strategy, turning losing butterflies into profitable vertices. Now with all the volume and volatility to the up side, traders can afford to sell to the down side. Some consolidation is on the horizon and i welcome a good base before moving to higher prices. Good luck this week. Look at the health and pharma sectors XLV, XBI, MJ, PPH --- Send in a voice message: https://anchor.fm/tradedoc/message
Thank you all for joining me. Today we spoke about: We discussed trades put on EWZ, and XLF Some potential set ups in XLV, XHB, XBI, XRT, and RSX The current Broad 28 Watch list of ETFs are liquid and provide options for great position controls: USO, XOP, GLD, GDX, XLE, XLU, XLI, XLB, XLV, XBI, MJ, IYR, XHB, XLP, XLY, XRT, XLF, XLK, QQQ, SPY, IWM, FXI, INDA, RSX, EFA, EEM, EWW, EWZ --- Send in a voice message: https://anchor.fm/tradedoc/message
Hope everyone is well and thank you again. On this episode of Thought and Trading, I spoke about trades in XBI, IWM, EWZ,INDA, and holding positions in XLU. Why leting winners run and close is better than tweaking and keeping. I spoke about Positive drift and when it's time to access and take action in your portfolio. Feel free to reach out with any comments or questions. Trade Doc,...Peace --- Send in a voice message: https://anchor.fm/tradedoc/message
In this episode, I went over the broad 28 ETF's in my watch list. Did this to get a feel for the present market conditions and structures. Many Charts are looking topped out while some show signs of breaking into higher prices. Discussed our position in EWZ, DRIP and retail sector. We discuses some Chinese ETFs: CHIC, CHIM, CHIQ, CHIX, CHII New trades opened on USO, EFA, and GLD The broad 28 are: USO, XOP, UNG. GLD. GDX, SLV, IYR, XLE, XLF, XLI, XLU, XLB, XLV, XBI, XHB, XRT, IWM, DIA,SPY, QQQ, EEM, FXI, EPI, RSX, MJ, EFA, EWZ, EWU --- Send in a voice message: https://anchor.fm/tradedoc/message
Investing in the biotech sector is not for the faint of heart. But these 3 investing strategies could help investors generate outsized returns with lower volatility. Stocks: IBB, XBI, IQV, PRAH, SYNH, ICLR, WST, VEEV, RGEN Check out more of our content here: TMF's podcast portal YouTube Twitter Join Our Motley Fool Podcast Facebook Group LinkedIn StockUp, The Motley Fool's weekly email newsletter
With biotech stocks sinking, the XBI just hit a 52 week low, and interest rates rising will we see an urgency for acquisitions to be done?
Trading Block: Stocks tumble ahead of Trump inauguration - Dow off 100. Netflix: Another crazy earnings for NFLX. Close = $133.26, straddle = $12.60 / 9.5%. Spiked to $145 in the after-hours, opened at $142 today. How a one-two, Trump-Yellen punch may move interest rates. Strategy Block: Uncle Mike Tosaw discusses the importance of event risk Odd Block: Puts trade in 3D Systems Corp (DDD); Calls trade in Avon Products, Inc (AVP); Calls trade in Union Pacific Corp (UNP) Mail Block/Options QuestionOfTheWeek: Earnings Season awakens! How do you play earnings using options? Are you an Earnings #Jedi or #Sith? Dark Side (Short Premium) Light Side (Long Premium) No Side - Avoid earnings Other (Reply/DM w/ideas) Listener questions and comments: Comment from Scott Francis - Generally most short with puts unless stock has been hammered then you get short squeeze Question from Piggyback - Learned about Lightspeed from the last show. Checked out their site and saw $.60 per contract but didn't see a ticket charge. Do they have one? Answer from Kevin:No ticket charge on options. We will tier commissions based on activity, at the lowest activity level we will charge $0.60/contract with $1.00 min. (So a 5 lot is $3.00, a 1 lot will be $1.00.) We can go down to $0.20/contact for active accounts, tiering schedule is on our website. Mention Option Insider when you call Lightspeed we will give them another nickel off the commission. Question from Ski -As for the repealing and recall of Obamacare. How do you price LEAPs on spider biotech? Someone bought 340 Jan 2018 55 Puts on XBI. Is this a bet on the repel of Obamacare? If so, are LEAP puts a good way to go? Question from Sean - If a trader thought that a price was going down, would a put not have been the best trade in the asian session? Around the Block: This Week in the Market -Jan 19: Jobless Claims, Housing Starts Earnings This Week Thursday - Union Pacific - Thursday am; IBM - Thursday pm riday General Electric, Procter & Gamble Co.
Trading Block: Stocks tumble ahead of Trump inauguration - Dow off 100. Netflix: Another crazy earnings for NFLX. Close = $133.26, straddle = $12.60 / 9.5%. Spiked to $145 in the after-hours, opened at $142 today. How a one-two, Trump-Yellen punch may move interest rates. Strategy Block: Uncle Mike Tosaw discusses the importance of event risk Odd Block: Puts trade in 3D Systems Corp (DDD); Calls trade in Avon Products, Inc (AVP); Calls trade in Union Pacific Corp (UNP) Mail Block/Options QuestionOfTheWeek: Earnings Season awakens! How do you play earnings using options? Are you an Earnings #Jedi or #Sith? Dark Side (Short Premium) Light Side (Long Premium) No Side - Avoid earnings Other (Reply/DM w/ideas) Listener questions and comments: Comment from Scott Francis - Generally most short with puts unless stock has been hammered then you get short squeeze Question from Piggyback - Learned about Lightspeed from the last show. Checked out their site and saw $.60 per contract but didn't see a ticket charge. Do they have one? Answer from Kevin:No ticket charge on options. We will tier commissions based on activity, at the lowest activity level we will charge $0.60/contract with $1.00 min. (So a 5 lot is $3.00, a 1 lot will be $1.00.) We can go down to $0.20/contact for active accounts, tiering schedule is on our website. Mention Option Insider when you call Lightspeed we will give them another nickel off the commission. Question from Ski -As for the repealing and recall of Obamacare. How do you price LEAPs on spider biotech? Someone bought 340 Jan 2018 55 Puts on XBI. Is this a bet on the repel of Obamacare? If so, are LEAP puts a good way to go? Question from Sean - If a trader thought that a price was going down, would a put not have been the best trade in the asian session? Around the Block: This Week in the Market -Jan 19: Jobless Claims, Housing Starts Earnings This Week Thursday - Union Pacific - Thursday am; IBM - Thursday pm riday General Electric, Procter & Gamble Co.
© 2020-2025 Ivy Podcast Discovery LLC
